CDK7 and head and neck squamous cell carcinoma: Interestingly, CDK7-selective inhibitors have been recently developed and are under current active testing in clinical trials.33,34 Moreover, CPTAC-HNSCC data analysis showed that CDK7 protein levels significantly increased in tumors compared to normal tissue counterparts (Supplementary Fig. 1f) and DepMap data analysis demonstrated that HNSCC cell lines are among the most sensitive to CDK7 inhibition (Supplementary Fig. 1g).